Answers are grounded in this paper and cite their sources.
Epigenetic and epitranscriptomic modifications represent fundamental regulatory layers that control chromatin organization, messenger RNA (mRNA) processing, and cellular identity. Aberrant regulation of these chemical marks, including DNA and RNA methylation, hydroxymethylation, and post-translational modifications (PTMs) of chromatin-associated proteins, is strongly implicated in the development and progression of cancer, neurodegenerative, autoimmune, and metabolic disorders. Mass spectrometry (MS) has emerged as a powerful analytical platform for decoding these complex systems, offering high sensitivity, quantitative accuracy, and molecular specificity for characterizing epigenetic and epitranscriptomic landscapes. In this review, we provide a comprehensive overview of MS-based strategies for qualitatively and quantitatively mapping DNA and RNA modifications at both global and site-specific levels. Key analytical approaches, including untargeted MS workflows, isotopic labeling techniques, targeted quantification, and ion mobility spectrometry (IMS), are discussed in the context of improving detection sensitivity, accuracy, and coverage. We further highlight the integration of MS with complementary multi-omic platforms, such as genomics, transcriptomics, and metabolomics, to enable systems-level insights into chromatin regulation and RNA modification networks. Emerging technologies, including single-cell and spatially resolved MS, are also discussed for their ability to resolve cellular heterogeneity and map epigenetic alterations in complex biological systems. Finally, we examine the translational potential of MS-based epigenomic and epitranscriptomic profiling for biomarker discovery and precision medicine. Despite ongoing challenges related to sample complexity, detection of low-abundance modifications, and data interpretation, continued advances in instrumentation, informatics, and integrative workflows are positioning MS at the forefront of molecular diagnostics, bridging the gap between mechanistic insight and clinical application.
No takes yet. Share an insight, caveat, or question.
Saed et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: